Clinical Trial

Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome. The study subjects will receive a single bolus of kisspeptin.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-11-03; most recent amendment 2026-07-09.
Status change: Not Yet Recruiting → Recruiting 2026-03-11
Trial Details
NCT Number NCT07224490
Lead Sponsor Stephanie B. Seminara, MD
Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Conditions Reproductive Disorder, Neurodegeneration, SARS-CoV 2, Long COVID
Enrollment 40 participants
Start Date 2026-03-10
Primary Completion 2030-05 (estimated)
Study Completion 2030-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-13